Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

223.78 -1.22 (-0.54%)
Streaming Delayed Price Updated: 9:57 AM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Can BioMarin Stock Live Up to Wall Street’s High Expectations?
BioMarin has greatly improved the fundamentals of its business, but continues losing value. Is the tide ready to turn, or is more of the same on the horizon? 
Via MarketBeat
News headline image
(ASND) - Analyzing Ascendis Pharma's Short Interest ↗
 
Via Benzinga
News headline image
A Glimpse of Ascendis Pharma's Earnings Potential ↗
 
Via Benzinga
News headline image
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts? ↗
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date. 
Via Benzinga
News headline image
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug ↗
Ascendis Pharma and Novo Nordisk sign exclusive global license for TransCon technology, aiming to advance obesity, type 2 diabetes, and cardiovascular treatments. 
Via Benzinga
News headline image
If You Invested $100 In This Stock 15 Years Ago, You Would Have $5,600 Today ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Looking Into Ascendis Pharma's Recent Short Interest ↗
 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
News headline image
BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth ↗
BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts. 
Via Benzinga
News headline image
3 Oversold Stocks with Big RSI Rebound Potential
Everybody loves finding a bargain or getting a good deal, and it's no different when it comes to stocks. The RSI indicator is a great way to find them. 
Via MarketBeat
Topics Economy
News headline image
BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish ↗
BioMarin Pharmaceutical aims to achieve $4 billion in revenue by 2027, driven by Voxzogo adoption, despite emerging competition from Ascendis Pharma. Goldman Sachs maintains a "Buy" rating with a $139... 
Via Benzinga
News headline image
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth $5,900 Today ↗
 
Via Benzinga
News headline image
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? ↗
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
News headline image
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term ↗
BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by late 2025 due to its dosing schedule and potential safety benefits. 
Via Benzinga
News headline image
Crude Oil Surges Over 1%; Instil Bio Shares Plunge ↗
 
Via Benzinga
News headline image
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year ↗
Ascendis Pharma reports positive topline data from the Phase 3 ApproaCH trial of TransCon CNP in children with achondroplasia. 
Via Benzinga
News headline image
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug ↗
The companies could soon face off in the growth treatment market for children with a genetic disorder. 
Via Investor's Business Daily
News headline image
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In ↗
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... 
Via Benzinga
News headline image
Why Ascendis Pharma Stock Tumbled by 11% Today ↗
A bottom-line whiff and reduced guidance made the company an outlier for the wrong reasons on Hump Day. 
Via The Motley Fool
News headline image
Ascendis Pharma Slashes Its Outlook Amid Pricing Fiasco, Sacrifices A Breakout ↗
Shares are poised to undercut their 50-day and 200-day lines, and the lower boundary of a base. 
Via Investor's Business Daily
News headline image
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut ↗
Ascendis Pharma reported lower-than-expected Q2 2024 sales of $38.76 million, missing the consensus estimate of $92.7 million due to a significant adjustment to prior sales estimates. The company... 
Via Benzinga
News headline image
Core & Main Reports Downbeat Results, Joins Rev Group, PagerDuty, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes 
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues ↗
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient... 
Via Benzinga
News headline image
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid Drug ↗
The company faced a number of regulatory setbacks that pushed its initial expected approval date out from April. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.